Every 10-Q that Annexon, Inc. (ANNX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ANNX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ANNX filings page.
Annexon, Inc. is a clinical-stage biopharmaceutical company developing complement-targeted immunotherapies for neuroinflammatory diseases. For the quarter ended June 30, 2026, it reported a net loss of $55.3 million, compared with $49.2 million a year earlier; the six‑month net loss was $99.5 million versus $103.5 million in 2025.
Research and development expenses were $46.6 million for the quarter and $82.4 million for the first half, down 11% year over year for the six‑month period, while general and administrative expenses rose to $20.9 million for the half, a 24% increase, mainly from higher professional services and stock-based compensation.
Cash, cash equivalents and short-term investments totaled $209.2 million as of June 30, 2026, and operating activities used $94.8 million of cash in the first half. Management states existing liquidity is expected to fund operations into 2028. After quarter-end, Annexon entered a term loan facility of up to $200.0 million, with an initial $50.0 million tranche funded, to further support its late-stage programs tanruprubart in Guillain-Barré Syndrome and vonaprument in geographic atrophy, along with oral candidate ANX1502.
Annexon reported first-quarter 2026 results showing a narrower loss and solid liquidity while advancing its late-stage pipeline. Net loss was $44.1 million versus $54.4 million a year earlier, as research and development spending fell to $35.8 million and general and administrative expenses rose modestly to $10.3 million.
Cash, cash equivalents and short-term investments totaled $225.0 million, and management believes this will fund operations into the second half of 2027. The company continues to focus on tanruprubart for Guillain-Barré Syndrome, vonaprument for geographic atrophy in dry AMD, and oral ANX1502 for autoimmune conditions, while maintaining additional capital access through at-the-market equity programs.
Annexon, Inc. reported Q3 2025 results with a net loss of $54.9M and operating expenses of $57.0M, driven by research and development of $49.7M and general and administrative of $7.3M. Interest and other income was $2.1M. For the nine months, net loss was $158.4M as R&D spending rose with late‑stage programs.
Cash, cash equivalents and short‑term investments were $188.7M as of September 30, 2025 ($139.4M cash and equivalents; $49.3M short‑term investments). Management projects existing liquidity will fund operations for at least twelve months from the financial statement issuance date.
R&D increased as the company advanced tanruprubart (GBS) toward MAA/BLA packages and continued the vonaprument (GA) Phase 3 ARCHER II trial. The company raised $13.5M net via its 2024 ATM in Q3 and subsequently sold additional shares for $13.9M net after quarter‑end. Shares outstanding were 119,632,804 as of November 5, 2025; 38,543,577 shares are issuable upon exercise of pre‑funded warrants at $0.001 per share, subject to beneficial ownership limits.
Annexon, Inc. is a clinical-stage biopharma with no approved products and significant historical losses. The company is advancing three lead programs: tanruprubart for Guillain-Barré Syndrome (GBS), which showed rapid and sustained functional improvement in a placebo-controlled Phase 3 trial and has Fast Track and orphan designations and a planned MAA submission in Europe in Q1 2026; vonaprument for geographic atrophy (GA), the only GA candidate to show significant vision preservation in Phase 2, with ARCHER II enrollment completed at 659 patients and topline data expected in H2 2026; and ANX1502, an oral C1s inhibitor with supportive Phase 1 PK/PD data and ongoing proof-of-concept study in cold agglutinin disease. The filing discloses recent equity offerings including pre-funded warrants (examples: 7,000,000 and 18,379,861 pre-funded warrants referenced) and ESPP availability of 2,959,996 shares. The company warns it will require substantial additional financing, relies on third-party manufacturers and collaborators, faces extensive regulatory and clinical risks, and has governance provisions that may limit stockholder control.